AxoGen Future Growth

Future criteria checks 4/6

AxoGen is forecast to grow earnings and revenue by 71.5% and 11.7% per annum respectively while EPS is expected to grow by 72.2% per annum.

Key information

71.5%

Earnings growth rate

72.2%

EPS growth rate

Medical Equipment earnings growth	16.5%
Revenue growth rate	11.7%
Future return on equity	n/a
Analyst coverage	Low
Last updated	03 May 2024

Recent future growth updates

Recent updates

Is AxoGen (NASDAQ:AXGN) Using Too Much Debt?

Apr 16

Positive Sentiment Still Eludes AxoGen, Inc. (NASDAQ:AXGN) Following 26% Share Price Slump

Mar 28

Market Might Still Lack Some Conviction On AxoGen, Inc. (NASDAQ:AXGN) Even After 33% Share Price Boost

Jan 26

Axogen: Renewed Covid-19 Worries Hitting, But The Growth Story Is Very Appealing

Aug 25

Earnings and Revenue Growth Forecasts

NasdaqCM:AXGN - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	225	10	25	N/A	3
12/31/2025	201	-1	14	N/A	5
12/31/2024	179	-18	-9	N/A	5
3/31/2024	164	-21	-22	-11	N/A
12/31/2023	159	-22	-21	-6	N/A
9/30/2023	152	-23	-24	-4	N/A
6/30/2023	148	-23	-27	-6	N/A
3/31/2023	144	-25	-33	-12	N/A
12/31/2022	139	-29	-37	-16	N/A
9/30/2022	134	-29	-41	-19	N/A
6/30/2022	128	-32	-45	-19	N/A
3/31/2022	127	-32	-44	-14	N/A
12/31/2021	127	-27	-42	-13	N/A
9/30/2021	128	-28	-34	-9	N/A
6/30/2021	131	-22	-27	-6	N/A
3/31/2021	119	-22	-33	-12	N/A
12/31/2020	112	-24	-32	-10	N/A
9/30/2020	108	-25	-36	-16	N/A
6/30/2020	103	-29	-37	-20	N/A
3/31/2020	108	-28	-29	-19	N/A
12/31/2019	107	-29	-25	-20	N/A
9/30/2019	102	-27	-26	-22	N/A
6/30/2019	96	-26	-30	-23	N/A
3/31/2019	90	-26	-27	-21	N/A
12/31/2018	84	-22	-24	-18	N/A
9/30/2018	77	-20	-21	-14	N/A
6/30/2018	71	-18	-15	-13	N/A
3/31/2018	65	-12	-13	-11	N/A
12/31/2017	60	-10	N/A	-9	N/A
9/30/2017	55	-14	N/A	-10	N/A
6/30/2017	50	-14	N/A	-10	N/A
3/31/2017	45	-14	N/A	-11	N/A
12/31/2016	41	-14	N/A	-11	N/A
9/30/2016	38	-12	N/A	-14	N/A
6/30/2016	34	-13	N/A	-14	N/A
3/31/2016	30	-13	N/A	-15	N/A
12/31/2015	27	-13	N/A	-13	N/A
9/30/2015	24	-16	N/A	-11	N/A
6/30/2015	21	-16	N/A	-11	N/A
3/31/2015	19	-17	N/A	-10	N/A
12/31/2014	17	-18	N/A	-10	N/A
9/30/2014	15	-15	N/A	-10	N/A
6/30/2014	13	-16	N/A	-11	N/A
3/31/2014	12	-15	N/A	-11	N/A
12/31/2013	11	-15	N/A	-10	N/A
9/30/2013	10	-14	N/A	-11	N/A
6/30/2013	9	-13	N/A	-10	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: AXGN is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.4%).

Earnings vs Market: AXGN is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: AXGN is expected to become profitable in the next 3 years.

Revenue vs Market: AXGN's revenue (11.7% per year) is forecast to grow faster than the US market (8.3% per year).

High Growth Revenue: AXGN's revenue (11.7% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if AXGN's Return on Equity is forecast to be high in 3 years time

AxoGen Future Growth

Future criteria checks 4/6

Key information

Recent future growth updates

Axogen, Inc. Provides Revenue Guidance for the Year 2024

Consensus EPS estimates fall by 39%

AxoGen, Inc. Provides Earnings Guidance for the Fiscal Year 2024

Forecast breakeven date pushed back to 2026

Forecast to breakeven in 2025

Axogen, Inc. Provides Revenue Guidance for the Full-Year 2023

Recent updates

Axogen, Inc. Provides Revenue Guidance for the Year 2024

First quarter 2024 earnings: EPS and revenues miss analyst expectations

New minor risk - Profitability

Axogen Announces First Surgical Implants of Avive+ Soft Tissue Matrix

AxoGen, Inc., Annual General Meeting, Jun 05, 2024

AxoGen, Inc. to Report Q1, 2024 Results on May 02, 2024

Is AxoGen (NASDAQ:AXGN) Using Too Much Debt?

New minor risk - Shareholder dilution

Positive Sentiment Still Eludes AxoGen, Inc. (NASDAQ:AXGN) Following 26% Share Price Slump

Chairman exercised options and sold US$302k worth of stock

Consensus EPS estimates fall by 39%

Vice President of Operations recently sold US$320k worth of stock

AxoGen, Inc. Announces Executive Changes

New minor risk - Shareholder dilution

AxoGen, Inc. Provides Earnings Guidance for the Fiscal Year 2024

Third quarter 2023 earnings released: US$0.095 loss per share (vs US$0.10 loss in 3Q 2022)

Forecast breakeven date pushed back to 2026

Market Might Still Lack Some Conviction On AxoGen, Inc. (NASDAQ:AXGN) Even After 33% Share Price Boost

Axogen, Inc. Announces Positive Topline Results from Its REPOSE Clinical Study

Axogen Announces Plan for Leadership Transition with CEO Karen Zaderej to Retire from Company by January 2025

Axogen, Inc. Appoints Kathy Weiler to its Board of Directors

Insider recently sold US$94k worth of stock

AxoGen, Inc. Announces CFO Changes

Forecast to breakeven in 2025

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Axogen, Inc. Provides Revenue Guidance for the Full-Year 2023

AxoGen, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Price target decreased by 13% to US$14.20

We Think AxoGen (NASDAQ:AXGN) Has A Fair Chunk Of Debt

Axogen, Inc. Announces Full Launch of Axoguard HA+ Nerve Protector

Independent Director recently bought US$66k worth of stock

Independent Director recently bought US$61k worth of stock

Axogen, Inc. Provides Revenue Guidance for the Year 2023

Market Cool On AxoGen, Inc.'s (NASDAQ:AXGN) Revenues

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

AxoGen, Inc. to Report Q2, 2023 Results on Aug 07, 2023

Director recently sold US$366k worth of stock

Director notifies of intention to sell stock

Director notifies of intention to sell stock

Director recently sold US$69k worth of stock

AxoGen, Inc. Provides Earnings Guidance for the Full-Year 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Executive VP & CFO exercised options and sold US$58k worth of stock

Full year 2022 earnings: EPS exceeds analyst expectations

Price target decreased by 8.5% to US$16.25

Axogen, Inc. Appoints Jens Schroeder Kemp as Chief Marketing Officer

Executive VP & CFO exercised options and sold US$318k worth of stock

AxoGen (NASDAQ:AXGN) Has Debt But No Earnings; Should You Worry?

AxoGen, Inc. to Report Q4, 2022 Results on Mar 14, 2023

Forecast to breakeven in 2025

Chairman exercised options to buy US$282k worth of stock.

Director notifies of intention to sell stock

Director notifies of intention to sell stock

Director notifies of intention to sell stock

Price target decreased to US$17.75

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

AxoGen, Inc. Updates Earnings Guidance for the Full Year 2022

Axogen, Inc. Announces Directorate Changes

AxoGen, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Is AxoGen (NASDAQ:AXGN) A Risky Investment?

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

AxoGen: Investors Are Positioned Long Leading Into Q2 FY22 Earnings

Eric Sandberg, Current Chief Commercial Officer Will Be Leaving AxoGen, Inc

Axogen estimates Q2 revenue above consensus, reaffirms guidance

Axogen, Inc. Appoints William Burke to Board of Directors

Price target increased to US$20.00

Price target decreased to US$17.80

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

AxoGen, Inc. Provides Earnings Guidance for the Full Year of 2022